Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Italy ETF (EWI) vs Heron Therapeutics Inc (HRTX) Price & Performance

Ishares Msci Italy ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Italy ETF vs Heron Therapeutics Inc — how do they compare? Ishares Msci Italy ETF trades at $63.12, while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Ishares Msci Italy ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

EWIHRTX
Sector
Broad Market / FactorHealth
52-Week High
$63.35$1.49
52-Week Low
$50.31$0.32
Market Cap
$61.47M
Enterprise Value
$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Italy ETF

EWI trades at $63.345, up 0.28% today, with a bullish technical signal driven by moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. The stock recently hit a 52-week high, as noted by Zacks Investment Research on June 10, 2026, amid improving industrial data and Italy's recovery narrative. A dividend of $1.17 is scheduled for June 2026, but key financial ratios like P/E and ROE are unavailable from current data.

The outlook is cautiously optimistic due to technical strength and positive sentiment, but risks include European economic volatility from ECB policy shifts and energy price fluctuations. Investors should weigh the bullish trend against potential overbought signals and macroeconomic headwinds.

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ishares Msci Italy ETF

EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.

Read more on EWI

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX